Andrew T. Lucas - Concepedia

Author

Andrew T. Lucas

University of North Carolina at Chapel Hill ORCID

Also Known As

A Lucas, A. LUCAS, A. Lucas, A.T. Lucas, Andrew Lucas, Andrew T Lucas, Andrew T. Lucas, Bender, David M., Jacobs, Timothy M, Lucas, Andrew T.

Publications

643

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill Dana-Farber Cancer Institute Virginia Tech Carolina Institute for NanoMedicine

About

Andrew T. Lucas is an author at University of North Carolina at Chapel Hill specializing in medicine, radiation oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	233
2	Engineering	2	2	43
3	Natural Sciences	2	2	120
4	Biochemistry	2	2	120
5	Health Sciences	1	1	11

Andrew T. Lucas

Publications

282

Citations

H-Index

Page 1

	Year	Citations
A Novel Heme-Regulatory Motif Mediates Heme-Dependent Degradation of the Circadian Factor Period 2 Jianhua Yang, Kevin D. Kim, Andrew T. Lucas, Molecular and Cellular Biology Molecular BiologyPrevents Hper2Redox BiologyOxidative StressHeme Trafficking	2008	94
A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues Andrew T. Lucas, Sara O’Neal, Charlene Santos, Journal of Pharmaceutical and Biomedical Analysis OncologyMedicineBioanalysisPathologyAnti-cancer Agent	2015	40
Biophysical and Molecular-Dynamics Studies of Phosphatidic Acid Binding by the Dvl-2 DEP Domain Daniel G. S. Capelluto, Xiaolin Zhao, Andrew T. Lucas, Biophysical Journal Proteinlipid InteractionBiochemistryPhosphatidic Acid BindingNatural SciencesBiophysical Aspect	2014	26
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer Linda Duska, Carolyn Krasner, David M. O’Malley, Gynecologic Oncology Phase Ib/iiGastrointestinal OncologyMedicineMetronomic TherapyPathology	2020	26
Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2 Christina L. Parker, Morgan D. McSweeney, Andrew T. Lucas, Nanomedicine Nanotechnology Biology and Medicine Cell-based Drug DeliveryNanomedicineEngineeringPolymer-drug ConjugateBispecific Antibody	2019	23
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs Andrew T. Lucas, Leah B. Herity, Zack A. Kornblum, International Journal of Pharmaceutics NanoparticlesNanomedicineEngineeringMedicineImmunology	2017	20
Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains Gina Song, Oscar Suzuki, Charlene Santos, Nanomedicine Nanotechnology Biology and Medicine Molecular PharmacologyPegylated Liposomal DoxorubicinMedicinePathogenesisPathology	2016	16
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models Andrew T. Lucas, Taylor F. White, Allison M. Deal, Nanomedicine Nanotechnology Biology and Medicine Tumor-associated MacrophagesDrug TargetingMedicineLiposomal AgentsAnti-cancer Agent	2016	15
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients Brittney Starling, Parag Kumar, Andrew T. Lucas, Cancer Chemotherapy and Pharmacology NanomedicineNormal WeightNanoparticle PharmacologyMedicineGynecology	2018	11
Does oxaliplatin pharmacokinetics (PKs) explain associations between body composition and chemotherapy toxicity risk in older adults with gastrointestinal (GI) cancers? Grant R. Williams, Mustafa Al‐Obaidi, Joseph E. Rower, Journal of Clinical Oncology Cancer ManagementGastroenterologyChemotherapy Toxicity RiskPharmacotherapyOxaliplatin Toxicity	2021	11

Page 1